19 Aug 2022

Participants sought: Immunobiology of pregnancy in MS and NMOSD

Pregnancy may have beneficial health effects for women with relapsing-remitting MS in the form of less long-term disability. 

Participants are sought for our research project, in which we are seeking to identify the biological mechanisms that underpin this benefit by following Australian women with and without MS over a 3-5 year period. In these women, we will track changes that occur to the immune system before, during, and after pregnancy, and compare these changes against the immune activity in women of the same age who do not have children. 

9-15 Aug 2022 Central Clinical School recent publications

Blood biomarkers enhance brain injury prognosis: Commentary
in The Lancet Neurology. Writeup and image: Medpage Today

Recent publications featuring research as notified by PubMed during 9-15 August 2022 from Central Clinical School affiliated researchers in the following departments.

The most recent validated publications for the school and departments can be seen on their publications pages, linked to from the headings below. Otherwise, read down the entry for recent notifications. The below is not a comprehensive list.

Congratulations to Muhammad Javaid, Robb Wesselingh and Xianglong Xu on their PhD completions

L-R: Muhammad Javaid, Robb Wesselingh and Xianglong Xu
Congratulations to our recently completed graduate research students Muhammad Javaid, Robb Wesselingh and Xianglong Xu - Well done! See below for detail of thesis topics, departments and supervisors.

Muhammad Javaid completed his PhD on 2 August, "Drug-resistant focal cortical dysplasia in epilepsy: insights from cellular models of neuronal development". He was supervised by Professor Patrick Kwan and Dr Ana Antonic-Baker (Department of Neuroscience).

30 days after surgery: crucial indicator of quality of care

Women, older people and those with more comorbidities are more likely to have complications, discharge to a care facility, hospital readmissions or death in the 30 days after surgery than other population groups, according to research published on 15 August by the Medical Journal of Australia.

See faculty story

Monash team receives BioCurate support to develop anti-thrombotic treatment

Professor Christoph Hagemeyer in the lab. His team has received
BioCurate Proof of Concept funding for developing a therapy that
targets acute thrombosis.

Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at Monash University, and his team have received Proof of Concept funding from BioCurate to develop a first-in-class antibody-based therapy that specifically targets acute thrombosis, the cause of many heart attacks, strokes and vascular blockages.

Myocardial infarction and stroke are the two single most common causes of death worldwide due, in part, to limitations with current medicines. Professor Hagemeyer’s team has developed a novel approach to inhibiting thrombosis by “uncoupling” this inhibition from adverse effects such as severe bleeding.

See story on the faculty news feed.

Related Posts Plugin for WordPress, Blogger...